Marco Ruella, MD

faculty photo
Assistant Professor of Medicine (Hematology-Oncology)
Department: Medicine

Contact information
South Tower 8-112
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
Philadelphia, PA 191004
Office: 215-746-4880
Fax: 215-573-3638
Lab: 215-573-8538
MD (Medical Degree)
University of Torino, Italy , 2007.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Dr. Ruella treat patients affected by hematological cancers and specializes in immunotherapy approaches.

Description of Research Expertise

Dr. Ruella's laboratory focuses on the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally design innovative combined immunotherapies for relapsing/refractory leukemia and lymphoma.

Dr. Marco Ruella obtained his medical degree with high honors and completed his specialization in clinical hematology at the University of Torino, Italy. He was attending physician at the Hematology and Cell Therapy Division of the Mauriziano Hospital and was an Instructor at the Biotechnology School at the University of Torino. From late 2012, he was a Post-doctoral Fellow, and then an Instructor at the University of Pennsylvania in the Center for Cellular immunotherapies (Drs. June and Gill). From 2017 to 2018 he served as Associate Director of Dr. June’s laboratory. In 2018, Dr. Ruella was appointed Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. Dr. Ruella was awarded many awards and honors, including the inaugural SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship (2014), the AACR-BMS Oncology Fellowship in Clinical Cancer Research (2015), the ASH Scholar Award (2016), a NIH K99-R00 award (2017), the “Paola Campese” Award Leukemia Research (2017), the Cancer Support Community Award (2018), the 2018 ASH Joanne Levy, MD, Memorial Award for Outstanding Achievement, the Gilead Sciences Research Scholar in Hematology/Oncology and the Gabrielle’s Angel Foundation Award (2020), and the Leukemia and Lymphoma Society, Translational Research Program (2021). Dr. Ruella is the author of numerous peer-reviewed publications on targeted immunotherapies for hematological cancers and is an inventor in several patents on CART therapy and the Scientific Founder of viTToria biotherapeutics.

Selected Publications

Watanabe K, Gomez AM, Kuramitsu S, Siurala M, Da T, Agarwal S, Song D, Scholler J, Rotolo A, Posey AD, Rook AH, Haun PL, Ruella M, Young RM, June CH. PMID: ; PMCID: .: Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma. Blood Adv. 7(14): 3416-3430, Jul 2023 Notes: doi: 10.1182/bloodadvances.2022008327.

Guruprasad P, Carturan A, Zhang Y, Kumashie KG, Cohen IJ, Ghilardi G, Kim KH, Lee JS, Lee Y, Kim JH, Chung J, Shestov M, Pajarillo R, Harris J, Lee YG, Wang M, Ballard H, Gupta A, Ugwuanyi O, Hong SJ, Chen L, Paruzzo L, Kammerman S, Patel RP, Shestova O, Vella L, Schuster SJ, Svoboda J, Porazzi P, Ruella M.: Modulation of the Btla-HVEM Axis to Enhance CAR T Cell Immunotherapy Against Cancer. American Society of Hematology Annual Meeting, San Diego, CA.(768), Dec 2023 Notes: "Poster Presentation"

Ghilardi G, Paruzzo L, Svoboda J, Chong Ea, Shestov A, Chen L, Cohen IJ, Gabrielli G, Nasta DS, Porazzi P, Landsburg DJ, Gerson J, Carter J, Barta SK, Yelton R, Pajarillo R, White GW, Ballard H, Weber E, Napier EB, Chong ER, Fraietta JA, Garfall AL, Porter DL, Milone MC, O’Connor R, Schuster SJ, Ruella M.: Bendamustine Is Less Toxic Than Fludarabine-Cyclophosphamide-Based Lymphodepletion before CD28-Costimulated CART19 through Reduced Inflammatory Cytokines. American Society of Hematology Annual Meeting, San Diego, CA.(4483), Dec 2023 Notes: "Poster Presentation"

Ruella M, Korell F, Porazzi P, Maus MV. Nat Rev Drug Discov.: Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat Rev Drug Discovery 22(12): 976-995, Dec 2023.

Yunlin Zhang, Ruchi P. Patel, Ki Hyun Kim, Hyungwoo Cho, Jae-Cheol Jo, Seong Hyun Jeong, Sung Yong Oh, Yoon Seok Choi, Sung Hyun Kim, Ji Hyun Lee, Mathew Angelos, Puneeth Guruprasad, Ivan Cohen, Ositadimma Ugwuanyi, Yong Gu Lee1, Raymone Pajarillo, Jong Hyun Cho, Alberto Carturan, Luca Paruzzo, Guido Ghilardi, Michael Wang, Soohwan Kim, Sung Min Kim, Hyun Jong Lee, Ji Ho Park, Lei Guang Cui, Tae Bum Lee, In Sik Hwang, Youngha Lee, Yong Jun Lee, Patrizia Porazzi, Dongfang Liu, Yoon Lee, Jong Hoon Kim, Jong Seo Lee, Dok Hyun Yoon, Junho Chung, Marco Ruella.: Safety and Efficacy of a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 with Fast On- and Off-rates against non-Hodgkin Lymphoma: A First-in-Human Study. Molecular Cancer 22(1): 200, Dec 2023.

Porazzi P, Isshiki Y, Ghilardi G, Nason S, Yang Z*, Carturan A, Chen L, Zhang Y, Patel R, Guruprasad P, Ugwuanyi O, Cohen IJ, Schuster SJ, Melnick AM, Beguelin W, Ruella M.: Inhibition of EZH2 Improves CART19 Immunotherapy By Reprogramming Lymphoma Tumor Cells and Enhancing T-Cell Functionality. American Society of Hematology Annual Meeting, San Diego, CA.(1018), Dec 2023 Notes: "Poster Presentation"

Patel RP, Ghilardi G, Zhang Y, Guruprasad P, Angelos MG, Pajarillo P, Gabunia K, Xu C, Blanchard T, Scholler J, Porazzi P, Linette G, Carreno BM, Ruella M. : Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies. American Society of Hematology Annual Meeting, San Diego, CA. (102), Dec 2023 Notes: "Poster Presentation"

Snook AE, Patel RP, Ghilardi G, Nimmagadda A, Yang S, Qian D, Porazzi P, Mazanet R, Schuster SJ, Barta SK, Vu T, Ruella M, Siciliano NA.: Senza5TM CART5: An Autologous CD5-Deleted Anti-CD5 CART Product with Enhanced Anti-T-Cell Lymphoma Activity. American Society of Hematology Annual Meeting, San Diego, CA.(3462), Dec 2023 Notes: "Poster Presentation"

Angelos MG, Patel RP, Chiang YH, Xie W, Pajarillo R, Shaw CE, Singh E, Xu J, Posey AD, Rook A, Rotolo A, Pillai V, Pileri SA, Teachey DT, Ruella M. : Fratricide-Resistant Anti-CD2 Chimeric Antigen Receptor T-Cells with Endogenous CD2 Knockout Are Highly Effective Against T-Cell Neoplasms. American Society of Hematology Annual Meeting, San Diego, CA.(885), Dec 2023 Notes: "Poster Presentation"

Cohen IJ, Bochi-Layec AC, Kim KH, Jenks S, Ugwuanyi O, Ghilardi G, Gabrielli G, Harris J, Wang LP, Zhang Y, Pajarillo R, Vlachonikola E, Porazzi P, Sanz I, Ghia P, Stamatopoulos K, Schuster SJ, Ruella M. : Precision Targeting of the Malignant Clone in Diffuse Large B Cell Lymphoma Using Chimeric Antigen Receptor T Cells Against the Clonotypic IGHV4-34 B Cell Receptor. American Society of Hematology Annual Meeting, San Diego, CA.(1020), Dec 2023 Notes: "Poster Presentation"

back to top
Last updated: 04/03/2024
The Trustees of the University of Pennsylvania